Back to Peptides

Exenatide

Metabolic & Weight Loss

Exenatide is a GLP-1 receptor agonist approved for type 2 diabetes treatment. It mimics incretin hormones to stimulate insulin secretion in a glucose-dependent manner, suppresses glucagon, delays gastric emptying, and aids in weight reduction. Available in twice-daily and weekly extended-release formulations, it also shows potential benefits in hepatic fat reduction and neuroprotection.

Reconstitute
null mL BAC + 1.2mg vial
Daily Range
5–10 mcg Subcutaneous (SQ)
Twice daily
Standard Dose
5 mcg
Cycle
4–8 weeks
then reassess
GLP-1 agonisttype 2 diabetesglycemic controlincretin mimeticweight loss

Dosing & Reconstitution Guide

Do not exceed 10mcg twice daily. Common side effects include nausea, which typically diminishes with continued use. Pancreatitis risk exists; discontinue immediately if severe abdominal pain occurs.

Standard / Gradual Approach

standard
PhaseDoseVolume
Week 15mcg
Week 25mcg
Week 310mcg
Week 410mcg

Protocol Summary

Subcutaneous (SQ): Twice daily · Dose range 5–10 mcg with gradual titration
Subcutaneous (SQ): Once weekly (extended-release formulation) · Dose range 2–2 mg with gradual titration
Cycle Length: 4–8 weeks typical; reassess before extending

Frequency & Cycling

SubQ Injection

Immediate-release: Inject twice daily within 60 minutes before morning and evening meals. Extended-release: Inject 2 mg SubQ once weekly. Continuous use; monitor glucose, A1c, and GI tolerance.

🧪 Quick Start

Potential Benefits & Use Cases

Exenatide is FDA-approved for type 2 diabetes. Use outside approved indications is off-label. Consult healthcare provider for appropriateness of use.
Improves glycemic control
Aids in weight loss
Reduces appetite
Potential neuroprotective effects
May reduce liver fat content
Clinical data Strong preclinical Limited data

Mechanism of Action

→Enhances glucose-dependent insulin secretion
→Suppresses inappropriately elevated glucagon secretion
→Slows gastric emptying and reduces postprandial glucose spikes

Lifestyle & Optimization

timing

Inject 60 minutes before meals. Consistent timing daily.

diet

Maintain caloric deficit of 300–500 calories. Lean proteins, vegetables, complex carbohydrates. Stay hydrated with 2–3 liters water daily.

exercise

Regular exercise 4–5 times weekly (both cardio and resistance).

sleep

Adequate sleep for metabolic recovery.

Peptide Research & Preclinical Studies

Evidence-Based Research Findings

Study TitleType
Glucagon-Like Peptide-1 Receptor AgonistsReference

Side Effects & Safety

Common Side Effects

• Nausea
• Vomiting
• Diarrhea

Contraindications & Warnings

• Risk of acute pancreatitis
• Caution in patients with renal impairment

Long-Term Safety Data

• Potential risk of thyroid C-cell tumors (observed in rodents)

🧮 Dose Calculator

Concentration
6.0
mcg/unit
Draw Volume
83
units (0.830 mL)
For a 500 mcg dose, draw 83 units on a U-100 insulin syringe
🧬

Bioavailability & Absorption

SubQ Injection
Good bioavailability via subcutaneous injection.
Oral Administration
Not available as an oral tablet; low oral bioavailability.
Half-Life
2.4 hours (immediate-release); approximately 6 to 7 days (extended-release).
Degradation
Primarily degraded by DPP-4 enzyme and cleared renally.
Tissue Specificity
Targets pancreatic beta cells, central appetite centers, and slows gastric emptying.
⚗️

Peptide Details

Molecular Weight
4186.6
Formula
C184H282N50O60
Sequence
HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS
⚖️

Legal Status & Regulatory

RegionStatus
FDAApproved
EUApproved
AustraliaApproved
CanadaApproved

Storage Instructions

Lyophilized (Powder)
Store pens at 2-8°C before first use. After initial use, may be stored at room temperature (15-30°C) for up to 30 days. Never freeze. Protect from light.
Reconstituted (Mixed)
Refrigerate at 2–8°C after reconstitution. Use within 28 days.